KLI

Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer

Metadata Downloads
Abstract
Purpose: We aimed to evaluate the clinical efficacy and safety of lenvatinib in patients with advanced anaplastic thyroid cancer (ATC) in real-world practice. Methods: This multicenter, retrospective cohort study included 14 patients with advanced ATC who received lenvatinib. We evaluated the response rate according to RECIST. Results: Ten patients had de novo ATC, and lenvatinib was used as a neoadjuvant treatment in eight patients. During a median follow-up of 6.7 months, patients received lenvatinib at a median dose of 13 mg daily. Overall, four patients (29%) showed partial response, nine (64%) had stable disease, and one (7%) had progressive disease. Tumor burden was reduced in 13 patients (93%), and the median best percent change from the baseline was ?15.8%. The median progression-free survival and overall survival were 5.7 months (95% confidence interval [CI], 2.2?8.3) and 6.7 months (95% CI, 3.0?8.4), respectively. All patients experienced adverse events (AEs). Most AEs were manageable but two AEs?tracheal perforation, and pneumothorax and pneumomediastinum?were life-threatening. One patient underwent flap surgery for reconstruction of their tracheal perforation, and another died of pneumothorax and pneumomediastinum, which seemed to be related to lenvatinib. Conclusions: In this multicenter real-world study, lenvatinib demonstrated limited clinical activity in advanced ATC. It effectively reduced the tumor burden but showed doubtful survival benefit. Although most AEs were manageable, one fatal AE was related to rapid tumor shrinkage. Further studies are needed to clarify the efficacy and optimal dose of lenvatinib in patients with advanced ATC.
Author(s)
강호철김미진김보현김원구김원배김태용송동은송영기안종화윤지희임동준전민지
Issued Date
2021
Type
Article
Keyword
Adverse eventsCancer patientsCare and treatmentComplications and side effectsDiabetesDrug dosagesEndocrinologyHumanities and Social SciencesInternal MedicineMedical researchMedicineMedicine &Public HealthExperimentalmultidisciplinaryOriginal ArticlePatientsPneumothoraxScienceSurgerySurvivalThyroidThyroid cancer
DOI
10.1007/s12020-020-02425-y
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7001
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2429060431&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Real-world%20experience%20of%20lenvatinib%20in%20patients%20with%20advanced%20anaplastic%20thyroid%20cancer&offset=0&pcAvailability=true
Publisher
ENDOCRINE
Location
이탈리아
Language
영어
ISSN
1355-008X
Citation Volume
71
Citation Number
2
Citation Start Page
427
Citation End Page
433
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.